Yale takes CRISPR beyond editing, turning cold tumors hot

Yale team aims CRISPR at tumor cells in an editing-free vaccine that boosts neoantigen production

A Yale team has developed a new use for CRISPR as a cancer vaccine that turns cold tumors hot by boosting neoantigen expression, rather than editing genes.

In the realm of cancer, CRISPR’s application to drug development has primarily been in target discovery and ex vivo engineering

Read the full 464 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE